Evidence map›Paper›PMID 38398109›Full record

ArticleCancers2024

Patterns of Temporal Lobe Reaction and Radiation Necrosis after Particle Radiotherapy in Patients with Skull Base Chordoma and Chondrosarcoma-A Single-Center Experience.

Matthias Mattke, Matteo Ohlinger, Nina Bougatf, Robert Wolf, Thomas Welzel, Falk Roeder, Sabine Gerum, Christoph Fussl, Natalee Annon-Eberharter, Malte Ellerbrock and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Matthias MattkeDepartment of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.
Matteo OhlingerDepartment of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Nina BougatfDepartment of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.ORCID 0000-0002-0718-7360
Robert WolfDepartment of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Thomas WelzelDepartment of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Falk RoederDepartment of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.
Sabine GerumDepartment of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.
Christoph FusslDepartment of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.
Natalee Annon-EberharterDepartment of Radiation Oncology, Paracelsus Medical University, Salzburger Landesklinikum (SALK), 5020 Salzburg, Austria.
Malte EllerbrockHeidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Oliver JäkelDepartment of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.ORCID 0000-0002-6056-9747
Thomas HabererHeidelberg Institute of Radiation Oncology (HIRO), 69120 Heidelberg, Germany.
Klaus HerfarthDepartment of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Matthias UhlDepartment of Radiation Oncology, Ludwigshafen Hospital, 67063 Ludwigshafen, Germany.
Jürgen DebusDepartment of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Katharina SeidensaalDepartment of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Semi HarrabiDepartment of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany.ORCID 0000-0003-1195-7150
Heidelberg University · DEParacelsus Medical University · ATGerman Cancer Research Center · DEKlinikum Ludwigshafen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe current study aims to evaluate the occurrence of temporal lobe reactions and identify possible risk factors for patients who underwent particle therapy of the skull base.

methods244 patients treated for skull base chordoma (

results51 patients with chordoma (35.4%) and 30 patients (30%) with chondrosarcoma experienced at least one temporal lobe reaction within the follow-up period (median 49 months for chondrosarcoma, 62 months for chordoma). Age, irradiated volume, and dose values were significant risk factors for the development of temporal lobe reactions with the highest significance for the value of DMax-7 being defined as the dose maximum in the temporal lobe minus the 7cc with the highest dose (

conclusionTemporal lobe reactions are a common side effect after particle therapy of the skull base. We were able to develop a multivariate model, which predicted radiation reactions with a specificity of 99% and a sensitivity of 52.2%.

Indexed as

carbon ionchondrosarcomachordomaheavy ionnecrosisprotonradiotherapyskull base

Identifiers

PMID38398109
PMCPMC10886807
OpenAlexW4391644611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.